Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialWinette T.A. van der Graaf, Peter Hohenberger, Jean‐Yves Blay et al.|The Lancet|2012Cited by 2.1k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 MutationsDavid M. Hyman, José Baselga, Igor Puzanov et al.|New England Journal of Medicine|2015Cited by 1.7k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialGeorge D. Demetri, Paolo G. Casali, Peter Reichardt et al.|The Lancet|2012Cited by 1.4k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trialIan Judson, Winette T.A. van der Graaf, Sandrine Marréaud et al.|The Lancet Oncology|2014Cited by 1.2k
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆Alessandro Gronchi, Javier Martín‐Broto, Silvia Stacchiotti et al.|Annals of Oncology|2021Cited by 978